Related Experiment Video
Updated: May 22, 2026
11:17
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
Low-molecular-weight heparins: differential characterization/physical characterization.
Marco Guerrini1, Antonella Bisio
1Istituto di Ricerche Chimiche e Biochimiche G. Ronzoni, Milan, Italy. guerrini@ronzoni.it
Handbook of Experimental Pharmacology
|May 9, 2012
Summary
Low-molecular-weight heparins (LMWHs) offer improved pharmacokinetics and safety over unfractionated heparin (UFH). Biophysical characterization is crucial for understanding LMWH drug profiles and structure-function relationships.
Area of Science:
- Pharmacology
- Biochemistry
- Drug Development
Background:
- Low-molecular-weight heparins (LMWHs) are derived from unfractionated heparin (UFH) via depolymerization.
- LMWHs offer advantages in pharmacokinetics, administration convenience, and reduced side effects compared to UFH.
Purpose of the Study:
- To review available methods for the biophysical characterization of LMWHs.
- To emphasize the importance of characterization for understanding LMWH drug profiles and structure-function relationships.
Main Methods:
- Review of chemical and physical characterization techniques for LMWHs.
- Discussion of methods, including those involving sample modification.
Main Results:
- Multiple chemical and physical methods exist for LMWH characterization.
- These methods are essential for differentiating LMWH drugs and understanding their properties.
Conclusions:
- Biophysical characterization is vital for defining individual LMWH drugs.
- Understanding LMWH structure-function relationships is key to optimizing their therapeutic use.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:09Hepatic Drug Clearance: Effect of Protein Binding
Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
01:19Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...